Canopy Growth at a Crossroads: Earnings Day and DEA Hearing Create a Pivotal June for a Stock That No Longer Trades on Hype

Canopy Growth shares trade 55% below 52-week high at €0.90. Upcoming Q4 results and US DEA hearing on marijuana reclassification will determine if downtrend can reverse.

After years of riding waves of legalisation speculation, Canopy Growth has entered a far less forgiving phase. The Canadian cannabis producer’s shares now trade at roughly €0.90, a level that leaves them more than 55% below the 52-week high of €2.00 and about 13.5% beneath the 200-day moving average of €1.04. The relative strength index sits at 42.9, neutral but tilted toward bearish territory. What little bounce the stock showed in recent sessions — a marginal 0.65% gain — looks more like a pause in a well-established downtrend than the start of a recovery.

Two events in the next three weeks will test whether Canopy can change that narrative. On 15 June the company reports its fourth-quarter and full-year results for fiscal 2026, alongside restated figures for prior periods. Then, on 29 June, the US Drug Enforcement Administration holds a formal hearing on the reclassification of marijuana from Schedule I to Schedule III — a process that paved the way for Trulieve Cannabis to become the first US operator listed on the New York Stock Exchange (under ticker TRLV) on 10 June. But where Trulieve’s listing signals a direct benefit from regulatory progress, Canopy’s structure as a primarily Canadian company means the hearing provides sentiment support at best, not a tangible boost to revenue.

The market’s patience has worn thin. Over the trailing twelve months, Canopy generated roughly US$278 million in revenue but posted a net loss exceeding US$327 million. Its cash position of around US$371 million buys time but does not stem the red ink. The company’s strategy to reach positive adjusted EBITDA by fiscal 2027 rests on cost cuts, a narrower focus, and the integration of MTL Cannabis — a deal closed in March 2026 that strengthens the medical platform in Canada and secures a supply of premium flower. These operational steps matter more now than any legislative promise. Investors, burned by years of unprofitable growth, are demanding evidence that management can turn a shrunken platform into a sustainable business.

There were bright spots, albeit minor ones. Canopy’s Claybourne brand won “Best Infused Pre-Roll” at the 2026 Grow Up Awards for its Frosted Flyers product, a sign that brand-building efforts are gaining traction. But product awards do not move share prices, and the broader backdrop remains challenging. German medical cannabis imports, a key outlet for Canadian producers, have cooled in recent months. While Europe offers a compliance-friendly market, it cannot single-handedly rescue a company that needs to improve margins and cash flow.

The stock’s market capitalisation of roughly €399 million leaves it vulnerable to sharp swings in sentiment, but the prevailing mood is cautious. The average analyst target of US$1.76 implies significant upside from current levels — but only if Canopy delivers results on 15 June that at least slow the loss trajectory. Until then, the shares are caught between fading regulatory fantasy and the hard grind of operational turnaround. The era of upfront premiums for distant legalisation is over. Canopy must now show it can earn its place in the portfolio.